Anti-C5b-9 (human)
Mouse monoclonal antibody
Cat.No. DIA 011-01
Preparation: Protein-A purified
Content: Available in 200 µL and 1 mL
Concentration: 1 mg/mL
Solvent: 10 mM phosphate buffer pH 7.4 containing 0.15 M NaCl and 0.09% sodium azide
Storage: In the dark at 4-8ºC
C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and DIA 011-01 is directed against a neoepitope exposed on C9 when incorporated into the TCC (1,2).
Purified C5b-9
DIA 011-01 binds both membrane-bound MAC and fluid-phase SC5b-9 complexes. DIA 011-01 cross-reacts with porcine (3) and equine TCC.
DIA 011-01 binds to a neoepitope exposed on C9
DIA 011-01 is well suited for quantifying TCC in ELISA and quantifying and characterizing TCC in various tissues by immunohistochemistry. DIA 011-01 is not recommended for Western blotting as the epitope is destroyed during the process.
| Method | Usability | Dilution guideline | References |
| ELISA | Yes | 4,5 | |
| Immunoblotting | No | ||
| Immunohistochemistry | Yes |
Users should determine the optimal dilutions for their own purposes
1. Mollnes TE, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 22:183-195.
2. Drogari-Aspiranthitou M, Kuijper EJ, Dekker N, Dankert J (2002) Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity. Infect Immunol 70:3752-3758.
3. Jansen JH, Høgåsen K, Mollnes TE (1993) Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 143:1356-1365.
4. Mollnes TE, Lea T, Frøland SS, Harbroe M (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22:197-202.
5. Mollnes TE (1997) Analysis of in vivo complement activation. Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C: Weir's Handbook of Experimental Immunology. Boston, MA: Blackwell Science, pp. 78.1-78.8.
Downloads
DIA 011-01.pdf (30.60 kB) Product specification
Complement flyer.pdf (422.22 kB) Complement flyer
Related Articles
Antibody MSDS
April 23 2008
